Oliver Luxxe Assets LLC Sells 72,068 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Oliver Luxxe Assets LLC trimmed its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 46.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,217 shares of the company’s stock after selling 72,068 shares during the quarter. Oliver Luxxe Assets LLC’s holdings in Amneal Pharmaceuticals were worth $1,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Westshore Wealth LLC purchased a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at about $13,833,000. Morgan Stanley boosted its holdings in Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Amneal Pharmaceuticals by 72.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after purchasing an additional 1,069,400 shares in the last quarter. Penn Capital Management Company LLC bought a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $12,655,000. Finally, Rubric Capital Management LP increased its stake in Amneal Pharmaceuticals by 9.1% in the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock valued at $94,737,000 after buying an additional 974,355 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on AMRX shares. UBS Group lifted their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. Finally, Barclays upped their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $18.14 on Monday. Amneal Pharmaceuticals, Inc. has a 12 month low of $8.21 and a 12 month high of $19.26. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. The business’s 50 day simple moving average is $16.79 and its 200 day simple moving average is $14.45. The company has a market cap of $5.79 billion, a price-to-earnings ratio of 37.02 and a beta of 1.27.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The business had revenue of $722.52 million during the quarter. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.